A phase II study of atezolizumab for pretreated advanced/recurrent non-small cell lung cancer with idiopathic interstitial pneumonias: rationale and design for the TORG1936/AMBITIOUS study

BACKGROUND: Approximately 10% of patients with non-small cell lung cancer (NSCLC) are complicated with comorbid interstitial pneumonia (IP) with a poor prognosis. The pharmacotherapy for advanced lung cancer occasionally induces fatal acute exacerbation of pre-existing IP. Due to the lack of prospec...

Descripción completa

Detalles Bibliográficos
Autores principales: Ikeda, Satoshi, Kato, Terufumi, Kenmotsu, Hirotsugu, Ogura, Takashi, Iwasawa, Shunichiro, Iwasawa, Tae, Kasajima, Rika, Miyagi, Yohei, Misumi, Toshihiro, Yamanaka, Takeharu, Okamoto, Hiroaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Immunotherapy for Lung Cancer: Progress, Opportunities and Challenges
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7222231/
https://www.ncbi.nlm.nih.gov/pubmed/32426051
http://dx.doi.org/10.1177/1758835920922022

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7222231/
https://www.ncbi.nlm.nih.gov/pubmed/32426051
http://dx.doi.org/10.1177/1758835920922022

Ejemplares similares